Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 3, 2006, Pages 260-265

  Yin, Hui ^a   He, Qun ^a   Li, Ting ^a   Leong, Anthony S Y ^b,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c Hunter Region Mail Centre ^*  (Australia)

Author keywords

Carcinoma in situ; Cytokeratin 20; Ki 67; Urinary bladder; WHO ISUP classification

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 20; KI 67 ANTIGEN;

ARTICLE; BLADDER; CARCINOMA IN SITU; CELL PROLIFERATION; CONTROLLED STUDY; DYSPLASIA; FOLLOW UP; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; STAINING; UROGENITAL TRACT TUMOR; UROTHELIUM; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION;

CARCINOMA IN SITU; DIAGNOSIS, DIFFERENTIAL; HUMANS; KERATIN-20; KI-67 ANTIGEN; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33748263588     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/00129039-200609000-00002     Document Type: Article

References (24)

1. Cheng L, Cheville JC, Neumann RM, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer. 1999;85:2469-2474.
2. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22:1435-1448.
3. Leong ASY, Cooper K, Leong FJWM. Manual of Diagnostic Antibodies for Immunohistology. 2nd ed. London: Greenwich Medical Media Ltd; 2003:171-172.
4. Harnden P, Eardley I, Joyce AD, et al. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol. 1996;78:870-875.
5. Harnden P, Mahmood N, Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet. 1999;353:974-977.
6. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
7. Bus MHT, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and Ki67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004;171:2461-2466.
8. Pfister C, Lacombe L, Vezina MC, et al. Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. Hum Pathol. 1999;30:1350-1355.
9. Pich A, Chiusa L, Navone R. Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol. 2004;15:1319-1329.
10. Santos L, Amaro T, Costa C, et al. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer. 2003;105:267-272.
11. Stavropoulos NE, Filiadis I, Ioachim E, et al. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer. Anticancer Res. 2002;22:3759-3764.
12. Eble JN, Sauter G, Epstein JI, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.
13. Alsheikh A, Mohamedali Z, Jones E, et al. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. Mod Pathol. 2001;14:267-272.
14. Desai S, Lim SD, Jimenez RE, et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. 2000;13:1315-1323.
15. Harnden P, Allam A, Joyce AD, et al. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathology. 1995;27:169-174.
16. Yin H, Leong ASY. Histologic grading of non-invasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol. 2004;121:679-687.
17. Mallofre C, Castillo M, Morente V, et al. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol. 2003;16:187-191.
18. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and nonneoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25:1074-1078.
19. Jones HL, Delahunt B, Bethwaite PB, et al. Polyclonal Ki-67 expression in transitional carcinoma of the bladder. Pathology. 1997;29:84-87.
20. Murphy WM, Grignon DJ, Perlman EJ. AFIP Atlas of Tumor Pathology. Series 4. Tumors of the Kidney, Bladder, and Related Urinary Structures. Washington, DC: American Registry of Pathology; 2004:228-230.
21. Cina SJ, Lancaster-Weiss KJ, Lecksell K, et al. Correlation of Ki67 and p53 with the new World Health Organization/International Society of Urological Pathology classification system for urothelial neoplasia. Arch Pathol Lab Med. 2001;125:646-651.
22. Krause FS, Feil G, Bichler KH. Immunohistochemical examinations (Ki67, p53, nm23) and DNA cytophotometry in bladder cancer. Anticancer Res. 2000;20:5023-5028.
23. Tut VM, Braithwaite KL, Angus B, et al. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br J Cancer. 2001;84:270-275.
24. Sun W, Zhang PL, Herrera GA. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder. Appl Immunohistochem Mol Morphol. 2002;10:327-331.